Pharmacokinetics and pharmacodynamics of inhaled corticosteroids

Journal of Allergy and Clinical Immunology

Volumn 101, Issue 4 SUPPL., 1998, Pages

  Derendorf, H ^a,c   Hochhaus, G ^a   Meibohm, B ^a   Mollmann H ^b   Barth, J ^b  

^a UNIVERSITY OF FLORIDA   (United States)

^b RUHR UNIVERSITY BOCHUM   (Germany)

^c UNIVERSITY OF FLORIDA HEALTH   (United States)

Author keywords

Inhaled corticosteroids; Mathematical modeling; Pharmacodynamics; Pharmacokinetics; Safety

Indexed keywords

BECLOMETASONE DIPROPIONATE; BECLOMETHASONE 17 MONOPROPIONATE; BUDESONIDE; CORTICOSTEROID; DEXAMETHASONE; FLUNISOLIDE; FLUTICASONE PROPIONATE; HYDROCORTISONE; PRODRUG; TRIAMCINOLONE ACETONIDE; UNCLASSIFIED DRUG;

CONFERENCE PAPER; DRUG ACCUMULATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG PROTEIN BINDING; DRUG RECEPTOR BINDING; HUMAN; INHALATIONAL DRUG ADMINISTRATION; MATHEMATICAL MODEL; MEAN RESIDENCE TIME; PHARMACODYNAMICS; PHARMACOKINETICS; PRIORITY JOURNAL; RECEPTOR AFFINITY;

ADMINISTRATION, INHALATION; ADMINISTRATION, ORAL; ADRENAL CORTEX HORMONES; ANTI-ASTHMATIC AGENTS; BIOLOGICAL AVAILABILITY; BLOOD PROTEINS; HUMANS; HYDROCORTISONE; LUNG; METABOLIC CLEARANCE RATE; PROTEIN BINDING; RECEPTORS, STEROID;

EID: 0031957146     PISSN: 00916749     EISSN: None     Source Type: Journal    
DOI: 10.1016/s0091-6749(98)70156-3     Document Type: Article

References (23)

1. Würthwein G, Rehder S, Rohdewald P. Lipophilicity and receptor affinity of glucocorticoids. Pharm Zeit Wissensch 1992;137:161-7.
2. Rohatagi S, Hochhaus G, Möllmann H, Barth J, Galia E, Erdmann M, et al. Pharmacokinetic and pharmacodynamic evaluation of triamcinolone acetonide after intravenous, oral and inhaled administration. J Clin Pharmacol 1995;35:1187-93.
3. Tomlinson RV, Runkel R, Chaplin MD, Bowens L, Kanagy J, Chu N. In vitro studies on the binding of cloprednol to human plasma proteins. J Steroid Biochem 1982;16:75-80.
4. Möllmann H, Derendorf H, Barth J, Meibohm B, Wagner M, Krieg M, et al. Pharmacokinetic/pharmacodynamic evaluation of the systemic effects of flunisolide after inhalation. J Clin Pharmacol 1997;37:893-903.
5. Ryrfeldt A, Andersson P, Edabaecker S, Toensson M, Davies D, Pauwels R. Pharmacokinetics and metabolism of budesonide, a selective glucocorticoid. Eur J Respir Dis 1982;63:86-95.
6. Rohatagi S, Bye A, Falcoz C, Mackie AE, Meibohm B, Möllmann H, et al. Dynamic modelling of cortisol reduction after inhaled administration of fluticasone propionate. J Clin Pharmacol 1996;36:938-41.
7. Martin LE, Harrison C, Tanner RJN. Metabolism of beclamethasone dipropionate by animals and man. Postgrad Med J 1975;51:11-20.
8. Falcoz C, Mackie A, McDowall J, McRae J, Yogendran L, Ventresca G, et al. Oral bioavailability of fluticasone propionate in healthy subjects. Br J Clin Pharmacol 1996;41:459P-60P.
9. Chaplin MD, Rooks W, Swenson EW, Cooper WC, Nerenberg C, Chu NI. Flunisolide metabolism and dynamics of a metabolite. Clin Pharmacol Ther 1980;27:402-13.
10. Derendorf H, Hochhaus G, Rohatagi S, Möllmann H, Barth J, Sourgens H, et al. Pharmacokinetics of triamcinolone acetonide after intravenous, oral, and inhaled administration. J Clin Pharmacol 1995;35:302-5.
11. Möllmann H, Meibohm B, Hochhaus G, Barth J, Falcoz C, Wagner M, et al. Pharmacokinetic and pharmacodynamic evaluation of fluticasone propionate after inhaled administration. Eur J Clin Pharmacol 1998. In press.
12. Brogden RN, McTavish D. Budesonide: an update review of its pharmacological properties, and therapeutic efficacy in asthma and rhinitis. Drugs 1992;44:375-407.
13. Chaplin MD, Cooper WC, Segre EJ, Oren J, Jones RE, Nerenberg C. Correlation of flunisolide plasma levels to eosinopenic response in humans. J Allergy Clin Immunol 1980;65:445-53.
14. Mackie A, Ventresca G, Fuller R, Bye A. Pharmacokinetics of intravenous fluticasone propionate in healthy subjects. Br J Clin Pharmacol 1996;41:539-42.
15. Jenner WN, Kirkham DJ. Immunoassay of beclomethasone 17,21-diproprionate and metabolites. In: Reid E, Robinson JD, Wilson I, editors. Bioanalysis of drugs and metabolites. New York: Plenum; 1988. p. 77-86.
16. Thorsson L, Edsbacker S, Conradson T. Lung deposition of budesonide from Turbuhaler is twice that from a pressurized metered-dose inhaler P-MDI. Eur Respir J 1994;7:1839-44.
17. Falcoz C, Kirby S, Smith J, Olsson P, Ventresca G. Pharmacokinetics and systemic exposure of inhaled beclomethasone dipropionate. Eur Respir J 1996;(Suppl 9):162S.
18. Rohatagi S, Bye A, Mackie A, Derendorf H. Mathematical modelling of cortisol circadian rhythm and cortisol suppression. Eur J Pharm Sci 1996;4:341-50.
19. Meibohm B, Hochhaus G, Möllmann H, Wagner M, Krieg M, Stöckmann R, et al. A PK/PD-approach to predict the cumulative cortisol suppression of inhaled corticosteroids. J Biopharm Clin Pharmacokinet. In press.
20. Meibohm B, Hochhaus G, Rohatagi S, Möllmann H, Barth J, Wagner M, et al. Dependency of cortisol suppression on the administration time of inhaled corticosteroids. J Clin Pharmacol 1997;37:704-10.
21. Hochhaus G, Möllmann H, Derendorf H, Gonzalez-Rothi RJ. Pharmacokinetic/pharmacodynamic aspects of aerosol therapy using glucocorticoids as a model. J Clin Pharmacol 1997;37:881-92.
22. Falcoz C, Brindley C, Mackie A, Bye A. Input rate into the systemic circulation of fluticasone propionate after a 1000 μg inhaled dose from the diskhaler. J Clin Pharmacol 1995;35:927.
23. Meibohm B, Hochhaus G, Möllmann H, Barth J, Derendorf H. Absorption profiles of inhaled corticosteroids. Pharm Res 1997;14:S141.